{"url_path":"/sec/rare/8-k/2026-05-18/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1515673/0001193125-26-228639-index.html","accession_number":"0001193125-26-228639","cik":"0001515673","ticker":"RARE","issuer_name":"Ultragenyx Pharmaceutical Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1515673/0001193125-26-228639-index.html","primary_entity_key":"0001515673","primary_entity_name":"Ultragenyx Pharmaceutical Inc."},"word_count":131,"has_tables":true,"body_markdown":"## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nAs reported below, at its Annual Meeting of Stockholders (the “Annual Meeting”) on May 14, 2026, the stockholders of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) approved the Third Amended and Restated 2023 Incentive Plan (the “Third A&R 2023 Plan”). The Third A&R 2023 Plan is described in more detail in Ultragenyx’s 2026 Proxy Statement (“Proxy Statement”), filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2026.\n\nThe foregoing description and the description incorporated by reference from the Proxy Statement are qualified in their entirety by reference to the Third A&R 2023 Plan, a copy of which is filed as Exhibit 10.1 and is incorporated herein by reference."}